A carregar...
Impact of empagliflozin on diabetic kidney disease
Empaglifolzin reduces metabolic derangements such as BP (blood pressure), hyperglycemia, body weight, uric acid, increases Ht (hamtaocrit), keton bodies, and restores altered tubule‐glomerular feedback, thereby protect against diabetes‐induced caidio‐renal injuries.[Image: see text]
Na minha lista:
| Publicado no: | J Diabetes Investig |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5583951/ https://ncbi.nlm.nih.gov/pubmed/28035769 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.12615 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|